Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-cell Neoplasms

PURPOSE: A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximally tolerated dose (MTD) for the combination of bortezomib and alvocidib in patients with B cell malignancies (multiple myeloma, indolent and mantle cell lymphoma). EXPERIMENTAL DESIGN: Patients received...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Holkova, Beata, Perkins, E. Brent, Ramakrishnan, Viswanathan, Tombes, Mary Beth, Shrader, Ellen, Talreja, Neha, Wellons, Martha D., Hogan, Kevin T., Roodman, G. David, Coppola, Domenico, Kang, Loveleen, Dawson, Jana, Stuart, Robert K., Peer, Cody, Figg, William D., Kolla, Sarah, Doyle, Austin, Wright, John, Sullivan, Daniel M., Roberts, John D., Grant, Steven
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3096752/
https://ncbi.nlm.nih.gov/pubmed/21447728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2876
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi